Editas Medicine, Inc.

NasdaqGS:EDIT Stok Raporu

Piyasa değeri: US$270.8m

Editas Medicine Yönetim

Yönetim kriter kontrolleri 2/4

Editas Medicine CEO'su Gilmore O’Neill, Jun2022 tarihinde atandı, in görev süresi 2.42 yıldır. in toplam yıllık tazminatı $ 2.39M olup, şirket hissesi ve opsiyonları dahil olmak üzere 26.8% maaş ve 73.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.13% ine doğrudan sahiptir ve bu hisseler $ 355.69K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.7 yıl ve 3.9 yıldır.

Anahtar bilgiler

Gilmore O’Neill

İcra Kurulu Başkanı

US$2.4m

Toplam tazminat

CEO maaş yüzdesi26.8%
CEO görev süresi2.4yrs
CEO sahipliği0.1%
Yönetim ortalama görev süresi1.7yrs
Yönetim Kurulu ortalama görev süresi3.9yrs

Son yönetim güncellemeleri

Recent updates

Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Nov 06
Analysts Are Betting On Editas Medicine, Inc. (NASDAQ:EDIT) With A Big Upgrade This Week

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Sep 26
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine: A Risk/Reward Worth Considering

Sep 25

Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Aug 23
Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 10
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

May 12
Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Apr 23
The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Mar 09
Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Feb 28

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Dec 15
New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

May 10
Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Jan 19
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Oct 18

Editas Medicine started at neutral at BofA due to competition in gene editing programs

Sep 29

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Sep 13
We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies

Aug 23

Editas Medicine Q2 2022 Earnings Preview

Aug 02

Baisong Mei joins Editas Medicine as Chief Medical Officer

Jul 18

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Jun 12
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Editas: Tackling Rare Eye Disease With Use Of Crispr Technology

Jun 06

Editas: The Unforeseen Detrimental Effect Of Patent Win

Mar 25

Editas: CRISPR Gene Editing Biotech With Promising Future

Mar 15

CEO Tazminat Analizi

Gilmore O’Neill'un ücretlendirmesi Editas Medicine'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$211m

Jun 30 2024n/an/a

-US$193m

Mar 31 2024n/an/a

-US$166m

Dec 31 2023US$2mUS$641k

-US$153m

Sep 30 2023n/an/a

-US$195m

Jun 30 2023n/an/a

-US$206m

Mar 31 2023n/an/a

-US$219m

Dec 31 2022US$9mUS$356k

-US$220m

Tazminat ve Piyasa: Gilmore 'nin toplam tazminatı ($USD 2.39M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.47M ).

Tazminat ve Kazançlar: Gilmore 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Gilmore O’Neill (60 yo)

2.4yrs

Görev süresi

US$2,392,309

Tazminat

Dr. Gilmore O’Neill, M.B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as i...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Gilmore O’Neill
President2.4yrsUS$2.39m0.13%
$ 355.7k
Erick Lucera
CFO & Executive VP1.5yrsUS$2.69m0.028%
$ 75.8k
Linda Burkly
Executive VP & Chief Scientific Officer1.3yrsUS$1.73m0.018%
$ 47.4k
Baisong Mei
Executive VP & Chief Medical Officer2.3yrsUS$1.14m0.052%
$ 139.6k
Feng Zhang
Co-Founder & Scientific Advisory Board Member11.8yrsVeri yokVeri yok
George Church
Co-Founder & Scientific Advisory Board Member11.8yrsVeri yokVeri yok
Gregory Whitehead
Executive VP and Chief Technical & Quality Officerless than a yearVeri yokVeri yok
Cristi Barnett
Corporate Communications & Investor Relationsno dataVeri yokVeri yok
Charlene Stern
Executive VP & General Counselno dataVeri yokVeri yok
Linea Aspesi
Executive VP & Chief People Officer1.7yrsVeri yokVeri yok
Caren Deardorf
Executive VP and Chief Commercial & Strategy Officer1.2yrsVeri yokVeri yok

1.7yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim: EDIT 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.7 yıl), bu da yeni bir ekibin varlığını gösteriyor.


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Gilmore O’Neill
Presidentno dataUS$2.39m0.13%
$ 355.7k
Feng Zhang
Co-Founder & Scientific Advisory Board Memberno dataVeri yokVeri yok
George Church
Co-Founder & Scientific Advisory Board Memberno dataVeri yokVeri yok
Emma Reeve
Independent Chairman of the Board3.2yrsUS$238.24k0%
$ 0
Andrew Hirsch
Independent Director7.5yrsUS$210.56k0.0024%
$ 6.6k
Jessica Hopfield
Independent Director6.8yrsUS$231.07k0.082%
$ 222.0k
Elliott Levy
Independent Director1.6yrsUS$264.88k0%
$ 0
David Scadden
Independent Director5.8yrsUS$213.06k0%
$ 0
Bernadette Connaughton
Independent Director3.1yrsUS$215.06k0%
$ 0
Meeta Chatterjee
Independent Director3.9yrsUS$205.56k0%
$ 0

3.9yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: EDIT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).